Optimizing outcomes in multiple sclerosis: Consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America

Therapeutic Advances in Neurological Disorders

Volumn 4, Issue 6, 2011, Pages 349-360

  Carra, Adriana ^a   Macaas Islas, Miguel Angel ^b   Gabbai, Alberto Alan ^c   Correale, Jorge ^d   Bolana, Carlos ^e   Sotelo, Eduardo Duriez ^f   Bonitto, Juan Garcaa ^g   Vergara Edwards, Fernando ^h   Vizcarra Escobar, Darwin ⁱ  

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^b Departamento de Neurociencias CUCS   (Mexico)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d CABA   (Argentina)

^e Hospital Pasteur Montevideo   (Uruguay)

^f Departamento de Neurologya de la Unidad   (Mexico)

^g Hospital Clínica de Marly   (Colombia)

^h UNIVERSIDAD DEL DESARROLLO   (Chile)

ⁱ UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

glatiramer acetate; immunomodulators; interferon beta; mitoxantrone; multiple sclerosis; natalizumab

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; DACLIZUMAB; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; RITUXIMAB;

ARTICLE; BRUCELLOSIS; CADASIL; CONSULTATION; COST EFFECTIVENESS ANALYSIS; CYANOCOBALAMIN DEFICIENCY; CYSTICERCOSIS; DIFFERENTIAL DIAGNOSIS; DISABILITY; DRUG MEGADOSE; EVOKED VISUAL RESPONSE; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; HEALTH CARE; HEALTH CARE SYSTEM; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; LACUNAR INFARCT; MALNUTRITION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; TREATMENT OUTCOME; TUBERCULOSIS; VASCULAR DISEASE; VASCULITIS; VIRUS INFECTION;

EID: 82955223367     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611423560     Document Type: Article

References (56)

1. Achiron A. Fredrikson S. (2009) Lessons from randomised direct comparative trials. J Neurol Sci 277(Suppl 1): S19–S24.
2. Bar-Or A. Calabresi P.A. Arnold D. Markowitz C. Shafer S. Kasper L.H. et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63: 395–400.
3. Benedict R. Cox D. Thompson L. Foley F. Weinstock-Guttman B. Munschauer F. (2004) Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler 10:675–678.
4. Ben-Zacharia A. Lublin F.D. National Multiple Sclerosis Society. 2009 Booklets series. Talking with your MS patients about difficult topics: Talking about initiating and adhering to treatment with injectable disease modifying agents. Available at: http://www.nationalmssociety.org/for-professionals/healthcare-professionals/publications/index.aspx. (Last accessed on September 12, 2011).
5. Bertolotto A. (2009) Implications of neutralising antibodies on therapeutic efficacy. J Neurol Sci 277(Suppl 1): S29–S32.
6. Cáceres F. Vanotti S. Gold L. Rao S. Reconem Work Group. (2003) The Reconem Study: cognitive impairment in multiple sclerosis, a national survey in Argentina. Neurology 60, A 54 (Abstract).
7. Cadavid D. Wolanksky L.J. Skurnick J. Lincoln J. Cheriyan K. Szczepanowski K. et al. (2009) Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 72: 1976–1983.
8. Clerico M. Faggiano F. Palace J. Rice G. Tintoré M. Durelli L. (2008) Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2: CD005278, DOI: 10.1002/14651858.CD005278.pub310.1002/14651858.CD005278.pub3
9. Cohen J.A. Barkhof F. Comi G. Hartung H.P. Khatri B. Montalban X. et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402–415.
10. Coles A.J. Compston D.A. Selmaj K.W. Lake S.L. Moran S. Margolin D.H. et al. (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786–1801.
11. Comi G. Filippi M. Barkhof F. Durelli L. Edan G. Fernández O. et al. (2001) Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357: 1576–1582.
12. Comi G. Martinelli V. Rodegher M. Moiola L. Bajenaru O. Carrá A. et al. (2009) PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374: 1503–1511.
13. Cristiano E. Patrucco L. Rojas J.I. (2008) A systematic review of the epidemiology of multiple sclerosis in South America. Eur J Neurol 15: 1273–1278.
14. Cristiano E. Patrucco L. Rojas J.I. Cáceres F. Carrá A. Correale J. et al. (2009) Prevalence of multiple sclerosis in Buenos Aires, Argentina using the capture-recapture method. Eur J Neurol 16: 183–187.
15. de Angelis T. Lublin F. (2008) Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. Mt Sinai J Med 75: 157–167.
16. Díaz V. Antinao J.F. Quezada R.A. Barahona J. (2010) Hospital-based prevalence and incidence of multiple sclerosis in Chile. American Academy of Neurology Annual Meeting, Toronto, poster P01.178.
17. Durelli L. Cocito D. Riccio A. (1986) High-dose intravenous methylprednisolone in the treatment of multiple sclerosis. Neurology 36: 238–243.
18. Filippi M. Rocca M.A. Arnold D.L. Bakshi R. Barkhof F. de Stefano N. et al. (2006) EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol 13: 313–325.
19. Freedman M.S. Patry D.G. Grand'Maison F. Myles M.L. Paty D.W. Selchen D.H. Canadian M.S. (2004) Working Group. Treatment optimization in multiple sclerosis. Can J Neurol Sci 31: 157–168.
20. Garcea O. Villa A. Cáceres F. Adoni T. Alegría M. Barbosa Thomas R. et al. (2009) Early treatment of multiple sclerosis: a Latin American Experts Meeting. Mult Scler 15(Suppl): S1–S12.
21. Goodin D.S. Hurwitz B. Noronha A. (2007) Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 35: 173–187.
22. Hauser S.L. Waubant E. Arnold D.L. Vollmer T. Antel J. Fox R.J. et al (2008) HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676–688.
23. Hirst C. Ingram G. Swingler R. Compston D.A. Pickersgill T. Robertson N.P. (2008) Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. J Neurol Neurosurg Psychiatry 79: 1137–1143.
24. IFN-beta Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661.
25. International Working Group for Treatment Optimization in MS. (2004) Treatment optimization in multiple sclerosis: report of an international consensus meeting. Eur J Neurol 11: 43–47.
26. Jacobs L.D. Cookfair D.L. Rudick R.A. Herndon R.M. Richert J.R. Salazar A.M. et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285–294.
27. Johnson K.P. Brooks B.R. Cohen J.A. Ford C.C. Goldstein J. Lisak R.P. et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45: 1268–1276.
28. Kappos L. Freedman M.S. Polman C.H. Edan G. Hartung H.P. Miller D.H. et al. (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370: 389–397.
29. Kappos L. Freedman M.S. Polman C.H. Edan G. Hartung H.P. Miller D.H. et al. (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8: 987–997.
30. Kappos L. Polman C.H. Freedman M.S. Edan G. Hartung H.P. Miller D.H. et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242–1249.
31. Kappos L. Radue E.W. O'Connor P. Polman C. Holfeld R. Calabresi P. et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387–401.
32. Krishnan C. Kaplin A.I. Brodsky R.A. Drachman D.B. Jones R.J. Pham D.L. et al. (2008) Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 65: 1044–1051.
33. Kurtzke J.F. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444–1452.
34. Luetic G. (2008) Multiple sclerosis in Latin America. Int MS J 15: 6–11.
35. McDonald W.I. Compston A. Edan G. Goodkin D. Hartung H.P. Lublin F.D. et al. (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50: 121–127.
36. Melcon M. Gold L. Carrá A. Cáceres F. Correale J. Cristiano E. et al. (2008) Argentine Patagonia: prevalence and clinical features of multiple sclerosis. Mult Scler 14: 656–662.
37. Melo A. Rodrigues B. Bar-Or A. (2008) Beta interferons in clinically isolated syndromes: a meta-analysis. Arq Neuropsiquiatr 66: 8–10.
38. Mikol D.D. Barkhof F. Chang P. Coyle P.K. Jeffery D.R. Schwid S.R. et al. (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7: 903–914.
39. Montalban X. Tintoré M. Swanton J. Barkhof F. Filippi M. Frederiksen J. et al. (2010) MRI criteria for MS in patients with clinically isolated syndromes. Neurology 74: 427–434.
40. O'Connor P. Filippi M. Arnason B. Comi G. Cook S. Goodin D. et al (2009) (BEYOND Study Group). 250 µg or 500 µg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8: 889–897.
41. Okuda D.T. Mowry E.M. Beheshtian A. Waubant E. Baranzini S.E. Goodin D.S. et al. (2009) Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 72: 800–805.
42. Polman C.H. Reingold S.C. Banwell B. Clanet M. Cohen J.A. Filippi M. et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. Ann Neurol 69: 292–302.
43. Polman C.H. Reingold S.C. Edan G. Filippi M. Hartung H.P. Kappos L. et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58: 840–846.
44. Poser C.M. Paty D.W. Scheinberg L. McDonald W.I. Davis F.A. Ebers G.C. et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227–231.
45. PRISMS Study Group. (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing / remitting multiple sclerosis PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneous in Multiple Sclerosis) Study Group. Lancet 359: 1498–1504.
46. Rieckmann P. Traboulsee A. Devonshire V. Oger J. (2008) Escalating immunotherapy of multiple sclerosis: further options for escalating immunotherapy. Ther Adv Neurol Disord 1: 181–192, DOI: 10.1177/175628560809835910.1177/1756285608098359
47. Rojas J.I. Patrucco L. Cristiano E. (2010) Oligoclonal bands and MRI in clinically isolated syndromes: predicting conversion time to multiple sclerosis. J Neurol 257: 1188–1191.
48. Rolak L.A. (2005) Differential diagnosis of multiple sclerosis. American Academy of Neurology Education Program, pp. 31–37.
49. Rovira A. Tintoré M. Alvarez-Cermeño J.C. Izquierdo G. Prieto J.M. (2010) Recommendations for using and interpreting magnetic resonance imaging in multiple sclerosis. Neurologia 25: 248–265.
50. Schumacher G.A. Beebe G. Kibler R.F. Kurland L.T. Kurtzke J.F. McDowell F. et al. (1965) Problems of experimental trials of therapy in multiple sclerosis: report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann N Y Acad Sci 122: 552–568.
51. Simon J.H. Li D. Traboulsee A. Coyle P.K. Arnold D.L. Barkhof F. et al. (2006) Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 27: 455–461.
52. Swanton J.K. Fernando K. Dalton C.M. Miszkiel K.A. Thompson A.J. Plant G.T. et al. (2006) Modification of MRI criteria for MS in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 77: 830–833.
53. Tintoré M. Rovira A. Río J. Tur C. Pelayo R. Nos C. et al. (2008) Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology 70: 1079–1083.
54. Toro J. Sarmiento O.L. Díaz del Castillo A. Satizábal C.L. Ramírez J.D. Montenegro A.C. et al. (2007) Prevalence of multiple sclerosis in Bogotá, Colombia. Neuroepidemiology 28: 33–38.
55. Velázquez Quintana M. Macías-Islas M.A. Rivera Olmos V. Lozano Zárate J. (2003) Esclerosis múltiple en México: un estudio multicéntrico. Rev Neurol 36: 1019–1022.
56. Wynn D. Kaufman M. Montalban X. Wollmer T. Simon J. Elkins J. et al. (2010) Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 9: 381–390. [Epub 15 February 2010].